骨髓增殖性肿瘤中西医诊治研究进展
Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms with Traditional Chinese and Western Medicine
摘要: 骨髓增殖性肿瘤(myeloproliferative neoplasms, MPN)是起源于造血干细胞的恶性骨髓增殖性疾病。经典的BCR-ABL阴性MPN包括真性红细胞增多症，原发性血小板增多症，原发性骨髓纤维化。大部分患者存在驱动基因突变，遗传学改变与其发病机制尚未明确，因此缺乏精准化治疗方案，且目前西医治疗效果不理想，不良反应多，而中西医联合治疗效果优于单用现代医学治疗，在缓解患者临床症状和减轻西医治疗不良反应方面存在一定优势。本文对近年来MPN的中西医病因病机及其治疗作一综述。
Abstract: Myeloproliferative neoplasms (MPN) are clonal hematologic malignancies, which are arisen from mutanthematopoietic stem. Classical BCR-ABL negative MPNs include polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Most patients have driver gene mutations, genetic change and its pathogenesis has not yet been clear, so the lack of precision treatment plan, and the current western medicine treatment effect is not ideal, has multiple adverse reactions. While the combined Chinese and western medicine treatment effect is better than single modern medical treatment, and has certain advantages reducing in clinical symptoms and western medicine treat-ment adverse reactions of patients. This review summarizes the etiology and pathogenesis and treatment of MPN in Traditional Chinese and Western medicine in recent years.
文章引用：王金, 朱振宇, 白玉盛. 骨髓增殖性肿瘤中西医诊治研究进展[J]. 临床医学进展, 2024, 14(1): 565-570. https://doi.org/10.12677/ACM.2024.141078

参考文献

[1] Tremblay, D., Yacoub, A. and Hoffman, R. (2021) Overview of Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 35, 159-176. [Google Scholar] [CrossRef] [PubMed]
[2] Tefferi, A. (2021) Primary Myelofibrosis: 2021 Update on Diagnosis, Risk-Stratification and Management. American Journal of Hematology, 96, 145-162. [Google Scholar] [CrossRef] [PubMed]
[3] 许鑫, 等. BCR-ABL融合基因阴性的骨髓增殖性肿瘤血栓形成相关因素及治疗的研究进展[J]. 医学综述, 2021, 27(18): 3634-3640.
[4] 黄丽颖, 张磊. 骨髓增殖性肿瘤出血并发症的危险因素及防治措施[J]. 临床血液学杂志, 2020, 33(11): 798-803.
[5] Stivala, S. and Meyer, S.C. (2021) Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms. Cancers, 13, Article No. 5035. [Google Scholar] [CrossRef] [PubMed]
[6] Rao, S. and Carlson, K. (2022) Mutant CALR’s “Sweet Tooth”. Blood, 140, 1187-1189. [Google Scholar] [CrossRef] [PubMed]
[7] Sugimoto, Y., et al. (2021) MPL Exon 10 Mutations Other than Canonical MPL W515L/K Mutations Identified by In-House MPL Exon 10 Direct Sequencing in Essential Thrombo-cythemia. International Journal of Hematology, 113, 618-621. [Google Scholar] [CrossRef] [PubMed]
[8] Greenfield, G., McMullin, M.F. and Mills, K. (2021) Molecular Pathogenesis of the Myeloproliferative Neoplasms. Journal of Hematology & Oncology, 14, Article No. 103. [Google Scholar] [CrossRef] [PubMed]
[9] Raivola, J., Haikarainen, T. and Silvennoinen, O. (2019) Charac-terization of JAK1 Pseudokinase Domain in Cytokine Signaling. Cancers, 12, Article No. 78. [Google Scholar] [CrossRef] [PubMed]
[10] Hu, X., et al. (2021) The JAK/STAT Signaling Pathway: From Bench to Clinic. Signal Transduction and Targeted Therapy, 6, 402. [Google Scholar] [CrossRef] [PubMed]
[11] Morris, R., et al. (2018) The Molecular Details of Cytokine Sig-naling via the JAK/STAT Pathway. Protein Science, 27, 1984-2009. [Google Scholar] [CrossRef] [PubMed]
[12] Marcuzzi, A., Rimondi, E., Melloni, E., Gonelli, A., Grasso, A.G., Barbi, E. and Maximova, N. (2022) New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib. Phar-maceuticals (Basel, Switzerland), 15, Article No. 374. [Google Scholar] [CrossRef] [PubMed]
[13] 肖志坚. 骨髓增殖性肿瘤的诊断与治疗新模式[J]. 循证医学, 2019, 19(2): 70-72.
[14] 黄晓春, 秦丽娟, 梁晔, 等. 干扰素α和羟基脲治疗JAK2V617F基因突变阳性骨髓增殖性肿瘤的临床分析[J]. 中外医疗, 2020, 39(3): 93-96.
[15] 向光朋, 杜晨霄, 张宇卉, 等. 干扰素-α治疗对骨髓增殖性肿瘤患者炎症因子及免疫细胞的影响研究[J]. 中国实用内科杂志, 2023, 43(4): 301-306.
[16] 王冬梅, 王洪芬, 李英华, 等. 干扰素α联合沙利度胺治疗JAK2V617F基因突变阳性Bcr/Abl阴性骨髓增殖性肿瘤的临床疗效研究[J]. 中国全科医学, 2018, 21(12): 1446-1450.
[17] 迟佳, 王京华. 芦可替尼治疗骨髓纤维化的研究进展[J]. 转化医学杂志, 2019, 10(4): 270-274.
[18] 杨志瑞, 朱海燕. 芦可替尼治疗骨髓增殖性肿瘤安全性和有效性的Meta分析[J]. 中国实验血液学杂志, 2018, 26(2): 493-501.
[19] Stivala, S., Codilupi, T., Brkic, S., Baerenwaldt, A., Ghosh, N., Hui, H.-S., et al. (2019) Targeting Com-pensatory MEK/ERK Activation Increases JAK Inhibitor Efficacy in Myeloproliferative Neoplasms. The Journal of Clinical Investigation, 129, 1596-1611. [Google Scholar] [CrossRef] 
[20] 尹晶晶, 唐倩, 谷佳礼, 等. 探究新型端粒酶抑制剂Nilo 22对白血病细胞的杀伤作用与机制[J]. 中国实验血液学杂志, 2021, 29(4): 1056-1064.
[21] 严雯雯, 陶毅明. 端粒酶抑制剂的研究进展[J]. 世界最新医学信息文摘, 2019, 19(6): 96-97, 99.
[22] 王庚, 田执梁. 骨髓增生异常综合征治疗药物的研究进展[J]. 现代药物与临床, 2022, 37(2): 433-438.
[23] Baerlocher, G.M., Rusbuldt, J., Bussolari, J. and Huang, F. (2020) Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors. International Jour-nal of Molecular Sciences, 21, Article No. 6550. [Google Scholar] [CrossRef] [PubMed]
[24] 王翰林, 龙程, 黄夏梦, 等. mTOR靶点莫司类药物在肿瘤中作用的进展[J]. 中国医院药学杂志, 2020, 40(22): 2382-2388.
[25] Tremblay, D. and Mascarenhas, J. (2021) Next Generation Therapeutics for the Treatment of Myelofi-brosis. Cells, 10, Article No. 1034. [Google Scholar] [CrossRef] [PubMed]
[26] Mascarenhas, J., Passamonti, F., Burbury, K., El-Galaly, T.C., Gerds, A., Gupta, V., et al. (2022) The MDM2 Antagonist Idasanutlin in Patients with Polycythemia Vera: Results from a Single-Arm Phase 2 Study. Blood Advances, 6, 1162-1174. [Google Scholar] [CrossRef] [PubMed]
[27] 陈信义, 麻柔, 李冬云. 规范常见血液病中医病名建议[J]. 中国中西医结合杂志, 2009, 29(11): 1040-1041.
[28] 郎海燕, 刘雅峰, 高宠, 等. 血液肿瘤疾病中医理论创新与发展[J]. 现代中医临床, 2019, 26(3): 55-58.
[29] 周庆兵, 胡晓梅. 周霭祥教授治疗恶性血液病经验简介[J]. 新中医, 2011, 43(4): 137-138.
[30] 陶文慧, 孙玲玲, 王艳玲, 等. 戴媺教授运用活血祛瘀解毒法治疗骨髓增殖性肿瘤的经验总结[J]. 中医临床研究, 2020, 12(12): 90-91.
[31] 王德秀, 麻柔, 唐旭东. 麻柔治疗骨髓增殖性肿瘤的临床经验[J]. 世界中西医结合杂志, 2016, 11(10): 1341-1344.
[32] 朱世荣, 李雨蒙, 王明镜, 等. 胡晓梅中西医结合治疗骨髓增殖性肿瘤经验[J]. 浙江中西医结合杂志, 2018, 28(11): 899-901.
[33] 袁鹏英, 杨向东, 张蕾. 杨文华治疗骨髓增殖性疾病经验[J]. 中华中医药杂志, 2009, 24(7): 897-898.
[34] 王志远, 宋亚琳, 程志. 陈安民治疗骨髓增殖性疾病思路及验案[J]. 大医生, 2020, 5(3): 78-80.
[35] 赖宗浪, 史雯, 马薇, 等. 李冬云运用理气活血法治疗骨髓增殖性肿瘤的临床经验[J]. 北京中医药杂志, 2014, 33(4): 263-266.
[36] 杜红, 周建华. 血府逐瘀汤加减联合羟基脲治疗原发性血小板增多症疗效观察[J]. 现代中西医结合杂志, 2020, 29(30): 3381-3384.
[37] 刘存. 青黄散联合羟基脲干预骨髓增殖性肿瘤的临床疗效观察及对JAK2V617F的影响[D]: [硕士学位论文]. 济南: 山东中医药大学, 2019.
[38] 吴晓勇, 王云龙. 基于网络药理学探讨青黄散治疗急性早幼粒细胞白血病的作用机制[J]. 贵州中医药大学学报, 2021, 43(4): 32-36.
[39] 伍振辉, 张欢, 吴欣平, 等. 基于网络药理学及体外实验探讨青黄散抗急性髓系白血病的分子机制[J]. 中国实验方剂学杂志, 2022, 28(7): 179-189.

为你推荐